## Abstract Human cord‐blood lymphocytes were infected with B95.8 Epstein‐Barr virus (EBV) before and after separation into B‐ and T‐cell populations. Lymphoblastoid cells exhibiting B‐cell characteristics appeared after 2 to 3 days of culture in the total population and in the separated B‐cell sub
The detection of the epstein-barr virus (ebv) nuclear antigen (ebna) by anti-complement immunofluorescence. Immunoglobulin class of antibodies and role of complement
✍ Scribed by A. Liabeuf; R. A. Nelson Jr.; F. M. Kourilsky
- Publisher
- John Wiley and Sons
- Year
- 1975
- Tongue
- French
- Weight
- 951 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The Epstein‐Barr virus (EBV)‐associated nuclear antigen (EBNA) was detected by anti‐complement immunofluorescence (ACIF) in Raji lymphoblastoid cell line, and the mechanism of the reaction explored, using Ig fractions of anti‐EBNA sera and purified components of complement. Following fractionation of serum from 13 donors, anti‐EBNA antibodies were always found to be associated with IgG, but were also detectable in the IgM fraction of four sera. Sequential addition of functionally pure complement components in the ACIF reaction showed that the classical sequence of complement activation is involved. Anti‐EBNA antibody reactions in Raji cell nuclei can also be detected by anti‐Ig immunofluorescence with a low level of sensitivity. The same pattern of granular fluorescence was observed when C3 (β~1A~/β~1C~), or C4 or IgG anti‐EBNA antibodies were revealed with the corresponding fluorescein‐conjugated reagents. Blocking of the ACIF reaction was achieved with Fab'2 anti‐EBNA antibody fragments, which therefore provided an appropriate specificity control for the detection of EBNA.
📜 SIMILAR VOLUMES
## Abstract The Epstein‐Barr virus nuclear antigen I (EBNA I) is the only latent EBV antigen consistently expressed in malignant tissues of the nasopharynx. A 20‐amino‐acid synthetic peptide, p107 contains a major epitope of EBNA I. We tested sera from 210 patients with nasopharyngeal carcinoma (NP
## Abstract Studies on the antibody responses to various Epstein‐Barr virus (EBV) antigens have been instrumental in the understanding of the seroepidemiology and diagnosis of this viral infection and the subsequent carrier state. While antibodies to the viral capsid antigen (VCA), early antigen (E